WAGENHEIM PHILIP 4

What Happened

• Director Philip Wagenheim sold a total of 65,000 Immunome (IMNM) shares in two open-market transactions. On 2026-03-20 he sold 36,800 shares at a weighted average price of $20.47 for proceeds of $753,296, and on 2026-03-23 he sold 28,200 shares at a weighted average price of $20.65 for proceeds of $582,330. Total reported proceeds were $1,335,626. These were sales (not purchases or option exercises).

Key Details

• Transaction dates and prices:
  • 2026-03-20: 36,800 shares sold; weighted avg price $20.47 (price range $20.07–$20.96). (Footnote F1.)
  • 2026-03-23: 28,200 shares sold; weighted avg price $20.65 (price range $20.15–$20.84). (Footnote F2.)
• Total shares sold: 65,000; total proceeds: $1,335,626.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: The filing gives weighted-average prices and price ranges and states that a full breakdown of shares sold at each separate price will be provided upon request by the SEC, issuer, or any security holder.
• Timeliness: Report filed 2026-03-23 for transactions reported on 2026-03-20; filing date falls within the SEC’s two-business-day Form 4 reporting window.

Context

• These were straightforward open-market sales by a company director. Sales can be routine (e.g., diversification or liquidity needs); the filing provides facts but does not state motivation. The filing does not indicate a 10% owner status or any option exercise or award associated with these transactions.